VERA - Vera Therapeutics, Inc.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan.

Oct 02, 2026 12:05 PM • globenewswire.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026

Oct 02, 2026 05:24 AM • globenewswire.com

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 15, 2026 04:01 PM • seekingalpha.com

What's Going on With Vera Therapeutics Stock on Tuesday?

Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.

Sep 15, 2026 08:28 AM • benzinga.com

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

Sep 15, 2026 08:03 AM • barrons.com

Why is Vera Therapeutics stock reversing its premarket gains?

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).

Sep 15, 2026 08:01 AM • invezz.com

Vera Stock Slides Despite Positive Phase 3 Results

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.

Sep 15, 2026 06:33 AM • schaeffersresearch.com

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis

Sep 15, 2026 02:30 AM • globenewswire.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Sep 04, 2026 12:05 PM • globenewswire.com

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Sep 01, 2026 03:30 AM • globenewswire.com

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.

Aug 17, 2026 10:20 AM • seekingalpha.com

E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA

E. Ohman J or Asset Management AB grew its holdings in Vera Therapeutics, Inc. (NASDAQ: VERA) by 99.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,777 shares of the company's stock after purchasing an additional 42,787 shares during

Aug 11, 2026 11:39 PM • defenseworld.net

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D.

Aug 07, 2026 12:05 PM • globenewswire.com

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.

Jul 11, 2026 10:02 AM • marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Jul 10, 2026 12:05 PM • globenewswire.com

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.

Jul 09, 2026 04:00 AM • globenewswire.com

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

Jul 07, 2026 03:12 PM • seekingalpha.com

US FDA approves Vera's kidney disease drug

The ​U.S. Food and Drug Administration ‌has approved Vera Therapeutics' drug to treat patients with ​a potentially life-threatening kidney ​disease, the regulator said ⁠on Tuesday, sending its ​shares up 6.2% in afternoon ​trading.

Jul 07, 2026 08:42 AM • reuters.com

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2 The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link.

Jul 07, 2026 08:37 AM • globenewswire.com

What's Going on with Vera Therapeutics Stock on Monday?

Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.

Jul 06, 2026 07:39 AM • benzinga.com

Vera Therapeutics price target raised to $84 from $78 at Raymond James

$84.00 (was $30.84)

Ryan Deschner · Raymond James

Aug 11, 2026 08:52 AM • TheFly

Vera Therapeutics price target raised to $43 from $35 at Wedbush

$43.00 (was $42.96)

Wedbush

Jul 08, 2026 07:51 AM • TheFly

Vera Therapeutics (VERA) PT Raised to $76 at Guggenheim

$76.00 (was $42.96)

Vamil Divan · Guggenheim

Jul 08, 2026 06:50 AM • StreetInsider

Vera Therapeutics (VERA) PT Raised to $125 at H.C. Wainwright

$125.00 (was $42.96)

Needham

Jul 08, 2026 06:42 AM • StreetInsider

Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright

$125.00 (was $42.96)

H.C. Wainwright

Jul 08, 2026 06:27 AM • TheFly

Jefferies Reiterates Buy Rating on Vera Therapeutics (VERA)

$60.00 (was $31.26)

Farzin Haque · Jefferies

Jun 02, 2026 03:56 PM • StreetInsider

Goldman Sachs on Vera Therapeutics (VERA): 'We are encouraged by today's update'

$90.00 (was $32.13)

Paul Choi · Goldman Sachs

Jun 02, 2026 11:15 AM • StreetInsider

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

$91.00 (was $38.54)

Evercore ISI

May 15, 2026 08:25 AM • TheFly

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

$95.00 (was $47.69)

Goldman Sachs

Dec 19, 2025 07:20 AM • TheFly

Vera Therapeutics price target raised to $33 from $23 at Wedbush

$33.00 (was $45.42)

Laura Chico · Wedbush

Dec 11, 2025 08:21 AM • TheFly

Vera Therapeutics price target raised to $97 from $75 at Evercore ISI

$97.00 (was $45.78)

Gavin Clark-Gartner · Evercore ISI

Dec 08, 2025 08:34 AM • TheFly

Vera Therapeutics (VERA) PT Raised to $73 at TD Cowen

$73.00 (was $42.61)

Pivotal Research

Dec 05, 2025 04:49 AM • StreetInsider

H.C. Wainwright Reiterates Buy Rating on Vera Therapeutics (VERA)

$90.00 (was $33.33)

H.C. Wainwright

Nov 28, 2025 06:35 AM • StreetInsider

Vera Therapeutics price target raised to $65 from $55 at Scotiabank

$65.00 (was $30.91)

Greg Harrison · Scotiabank

Jun 03, 2025 10:03 AM • TheFly

Vera Therapeutics (VERA) PT Raised to $34 at Wedbush

$34.00 (was $42.87)

Laura Chico · Wedbush

Mar 21, 2024 02:01 AM • StreetInsider

Raymond James Upgrades Vera Therapeutics (VERA) to Strong Buy

$37.00 (was $30.18)

Ryan Deschner · Raymond James

Jan 26, 2024 01:47 AM • StreetInsider

Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst

$29.00 (was $15.84)

Ryan Deschner · Raymond James

Dec 18, 2023 08:59 AM • Benzinga

Jefferies Downgrades Vera Therapeutics to Hold, Lowers Price Target to $6

$6.00 (was $6.37)

Jefferies

Jan 04, 2023 05:29 AM • Benzinga

HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $15

$15.00 (was $18.30)

H.C. Wainwright

Jan 04, 2023 01:42 AM • Benzinga

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $38

$38.00 (was $17.62)

J.P. Morgan

Nov 18, 2022 03:12 AM • Benzinga